Thermo Fisher Scientific Inc. (TMO) Stock Analysis

Thermo Fisher Scientific (TMO) is the global leader in life sciences tools and services, generating more than USD 45 billion in annual revenue across instruments, consumables, diagnostics, clinical research, and contract manufacturing. Its integrated portfolio supports the full drug-development lifecycle, while **84% of sales come from recurring services and consumables**, reducing exposure to capital-equipment replacement cycles. The company holds a 15%–18% global market share and uses regulatory validation, enterprise bundling, and distribution scale to sustain customer retention near 95%. Financial momentum improved materially in Q2 2026: revenue increased 10.5% unrounded to USD 11.99 billion, organic growth reached 5%, adjusted operating margin expanded 90 basis points to 22.8%, and adjusted EPS rose 13% to USD 6.03, exceeding consensus by USD 0.32. Management raised fiscal 2026 revenue guidance to USD 47.4–48.1 billion and adjusted EPS guidance to USD 24.93–25.33. The stock closed at USD 577.32 after a 9.66% earnings-day rally, versus a revised analyst consensus target of USD 603.15. **The investment case is a high-quality compounder recovering with biopharma spending, although leverage and valuation-dependent execution remain important constraints.**